



Formulary Change Notice

Gold Kidney of Arizona may remove drugs from our formulary (list of covered drugs) or add rules about whether and when certain drugs are covered during the year. The chart below contains upcoming changes to the Gold Kidney of Arizona formulary. You may not be taking these drugs now. We provide you with these updates so that you know about future changes to our drug list. Please see Section 4 of your Monthly Prescription Drug Summary (Member Explanation of Benefits) for specific changes to drugs that you are currently taking.

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
23380	2/1/2023	DALIRESP 500 MCG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ROFLUMILAST 500 MCG ORAL TABLET-2
23380	2/1/2023	GILENYA 0.5 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	FINGOLIMOD 0.5 MG ORAL CAPSULE-5
23380	2/1/2023	REVLIMID 20 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 20 MG ORAL CAPSULE-5
23380	2/1/2023	REVLIMID 2.5 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 2.5 MG ORAL CAPSULE-5
23380	3/1/2023	DALIRESP 250 MCG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ROFLUMILAST 250 MCG ORAL TABLET-2
23380	4/1/2023	BIDIL 20-37.5MG ORAL TABLET	FORMULARY DELETION	FORMULARY DELETION	N/A

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
23380	4/1/2023	ESBRIET 267 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PIRFENIDONE 267 MG ORAL CAPSULE-5
23380	5/1/2023	HETLIOZ 20 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TASIMELTEON 20 MG ORAL CAPSULE-5
23380	5/1/2023	LATUDA 20 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LURASIDONE HCL 20 MG ORAL TABLET-2
23380	5/1/2023	LATUDA 40 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LURASIDONE HCL 40 MG ORAL TABLET-2
23380	5/1/2023	LATUDA 60 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LURASIDONE HCL 60 MG ORAL TABLET-2
23380	5/1/2023	LATUDA 80 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LURASIDONE HCL 80 MG ORAL TABLET-2
23380	5/1/2023	LATUDA 120 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LURASIDONE HCL 120 MG ORAL TABLET-2
23380	4/22/2023	VIMPAT 200MG/20ML INTRAVEN. VIAL	BRAND DELETION, ADD NEWLY APPROVED GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 200MG/20ML INTRAVEN. VIAL-2

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
23380	6/1/2023	AUBAGIO 7 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TERIFLUNOMIDE 7 MG ORAL TABLET-5
23380	6/1/2023	AUBAGIO 14 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TERIFLUNOMIDE 14 MG ORAL TABLET-5
23380	7/1/2023	UCERIS 2 MG RECTAL FOAM/APPL	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	BUDESONIDE 2 MG RECTAL FOAM/APPL-2
23380	7/1/2023	NOXAFIL 200 MG/5ML ORAL SUSP	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	POSACONAZOLE 200 MG/5ML ORAL SUSP-5
23380	8/1/2023	IRESSA 250 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	GEFITINIB 250 MG ORAL TABLET-5
23380	8/1/2023	CELONTIN 300 MG ORAL CAPSULE	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	METHSUXIMIDE 300 MG ORAL CAPSULE-2
23380	9/1/2023	PREZISTA 600 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DARUNAVIR 600 MG ORAL TABLET-5
23380	9/1/2023	PREZISTA 800 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DARUNAVIR 800 MG ORAL TABLET-5

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
23380	10/1/2023	PLASMA-LYTE 148 INTRAVEN. IV SOLN	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MULTIPLE ELECTROLYTES T1 PH5.5 INTRAVEN. IV SOLN-4
23380	10/1/2023	AMBISOME 50 MG INTRAVEN. VIAL	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	AMPHOTERICIN B LIPOSOME 50 MG INTRAVEN. VIAL-5